507 related articles for article (PubMed ID: 21381982)
1. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
[TBL] [Abstract][Full Text] [Related]
2. Current status of epigenetic treatment in myelodysplastic syndromes.
Kuendgen A; Lübbert M
Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
Leone G; Teofili L; Voso MT; Lübbert M
Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
[TBL] [Abstract][Full Text] [Related]
4. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.
Khan H; Vale C; Bhagat T; Verma A
Semin Hematol; 2013 Jan; 50(1):16-37. PubMed ID: 23507481
[TBL] [Abstract][Full Text] [Related]
5. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
Liu HB; Urbanavicius D; Tan P; Spencer A; Dear AE
Int J Oncol; 2014 Oct; 45(4):1742-8. PubMed ID: 25051119
[TBL] [Abstract][Full Text] [Related]
7. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic therapy in myelodysplastic syndromes.
Musolino C; Sant'antonio E; Penna G; Alonci A; Russo S; Granata A; Allegra A
Eur J Haematol; 2010 Jun; 84(6):463-73. PubMed ID: 20192987
[TBL] [Abstract][Full Text] [Related]
9. Panobinostat for the treatment of acute myelogenous leukemia.
Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
Ungerstedt JS
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304859
[TBL] [Abstract][Full Text] [Related]
11. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.
Ball B; Zeidan A; Gore SD; Prebet T
Leuk Lymphoma; 2017 May; 58(5):1022-1036. PubMed ID: 27654579
[TBL] [Abstract][Full Text] [Related]
12. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
Prebet T; Vey N
Expert Opin Investig Drugs; 2011 Feb; 20(2):287-95. PubMed ID: 21192773
[TBL] [Abstract][Full Text] [Related]
13. Clinical development of decitabine as a prototype for an epigenetic drug program.
Rosenfeld CS
Semin Oncol; 2005 Oct; 32(5):465-72. PubMed ID: 16210087
[TBL] [Abstract][Full Text] [Related]
14. Optimizing hypomethylating agents in myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2012 Mar; 19(2):65-70. PubMed ID: 22248878
[TBL] [Abstract][Full Text] [Related]
15. 5-Azacytidine for the treatment of myelodysplastic syndromes.
Krawczyk J; Keane N; Freeman CL; Swords R; O'Dwyer M; Giles FJ
Expert Opin Pharmacother; 2013 Jun; 14(9):1255-68. PubMed ID: 23621771
[TBL] [Abstract][Full Text] [Related]
16. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
17. Use of hypomethylating agents in myelodysplastic syndromes.
Atallah E; Garcia-Manero G
Clin Adv Hematol Oncol; 2007 Jul; 5(7):544-52. PubMed ID: 17679928
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies.
Gore SD
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S30-5. PubMed ID: 16341238
[TBL] [Abstract][Full Text] [Related]
19. More is better: combination therapies for myelodysplastic syndromes.
Ornstein MC; Mukherjee S; Sekeres MA
Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
[TBL] [Abstract][Full Text] [Related]
20. Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
Alencar C; Abramowtiz M; Parekh S; Braunshweig I; Jacobson M; Silverman L; Verma A
Am J Hematol; 2009 Oct; 84(10):688-9. PubMed ID: 19722261
[No Abstract] [Full Text] [Related]
[Next] [New Search]